Document is current

Article History

Received: 13 January 2025

Accepted: 17 March 2025

First Online: 28 March 2025

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Not applicable.

: Not applicable.

: All authors are advisors to Boston Scientific Corporation. Marnix Lam is an advisor to Terumo, Novartis, Oncosil, BD, and Quirem, and receives research support from Boston Scientific, Terumo, Quirem, and Novartis. Riad Salem is a consultant for AstraZeneca, Genentech, Sirtex, Cook, Eisai, Bard, and QED Therapeutics. Beau Toskich is a consultant for AstraZeneca, Genentech, Eisai, Sirtex, Turnstone Biologics, Johnson and Johnson, HistoSonics, and Vivos. S. Cheenu Kappadath is a consultant for Sirtex, ABK Biomedical, and Terumo. Carlo Chiesa is a consultant for Terumo, and he received a research grant in 2017 from Boston Scientific. Kirk Fowers is a non-commercial employee of Boston Scientific Corporation. Joseph M. Herman is a employee of HistoSonics, and received institutional support for the Canopy Cancer Collective Learning Health Network. Edward Kim is an advisory board member and speaker for Boston Scientific, a consultant for Bristol-Myers Squibb, and an advisory board member for Genentech and Eisai. Thomas Leung is a consultant for Sirtex, AstraZeneca, Eisai, and Ipsen. Siddharth Padia is a consultant for Teleflex Medical, Guerbet, Varian Medical Systems, and Johnson and Johnson. Bruno Sangro received consulting fees from Adaptimmune, AstraZeneca, Bayer, BMS, Eisai, Exelixis, Eli Lilly, Ipsen, Merch, Onxeo, Roche, Sirtex, and Terumo; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Eli Lilly, Incyte, Ipsen, Roche, and Sirtex; and institutional grants from BMS and Sirtex. Daniel Y. Sze serves on Independent Data Safety Monitoring Boards for W.L. Gore, FluidX, and Replimune, and is the Editor in Chief of the Journal of Vascular and Interventional Radiology.